Clinical trial
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
NCT00678392 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 3, 2008
- Completion date
- February 25, 2016
- Enrollment
- 723 (actual)
- Sites
- 294
Conditions
As the registry lists them; a condition with its own page is linked.